

NCCN Guidelines for Kidney Cancer v.2.2020 – Follow Up on 07/19/19

Guideline Page and Request	Panel Discussion/References	Institution Vote			
		YES	NO	ABSTAIN	ABSENT
<b>KID-C, 1 of 2</b> Internal request:  Comment to consider adding bevacizumab-bvzr as a subsequent therapy option for patients who have relapsed or stage IV clear cell RCC, similar to bevacizumab.	Based on review of the data and recent FDA approval, the panel consensus supported the addition of bevacizumab-bvzr as a subsequent therapy option for patients with clear cell RCC with the same category of evidence and consensus as the reference product, bevacizumab, for this indication.	15	3	4	5
<b>KID-C, 1 of 2</b> External request:  Submission from Amgen (7/19/19) to consider adding bevacizumab-awwb as an appropriate substitute to bevacizumab for patients with metastatic renal cell carcinoma.	This submission was addressed by the panel in a previous version of the NCCN Guidelines for Kidney Cancer (v.1.2020). <ul style="list-style-type: none"> <li>See Submission for references.</li> </ul>				
<b>KID-C, 2 of 2</b> Internal request:  Comment to consider adding bevacizumab-bvzr as a systemic therapy option for patients who have relapsed or stage IV non-clear cell RCC, similar to bevacizumab.	Based on review of the data and recent FDA approval, the panel consensus supported the addition of bevacizumab-bvzr as a subsequent therapy option for patients with non-clear cell RCC with the same category of evidence and consensus as the reference product, bevacizumab, for this indication.	13	5	4	5
<b>KID-C, 2 of 2</b> Internal request:  Comment to consider adding bevacizumab-bvzr as a systemic therapy option in combination with erlotinib for patients who have relapsed or stage IV non-clear cell RCC, similar to bevacizumab.	Based on review of the data and recent FDA approval, the panel consensus supported the addition of bevacizumab-bvzr in combination with erlotinib as a systemic therapy option for patients with advanced papillary RCC including hereditary leiomyomatosis and renal cell cancer (HLRCC) with the same category of evidence and consensus as the reference product, bevacizumab, for this indication.	16	3	3	5

<b>KID-C, 2 of 2</b> Internal request:  Comment to consider adding bevacizumab-bvzr as a systemic therapy option in combination with everolimus for patients who have relapsed or stage IV non-clear cell RCC, similar to bevacizumab.	Based on review of the data and recent FDA approval, the panel consensus supported the addition of bevacizumab-bvzr as a systemic therapy option in combination with everolimus for patients with non-clear cell RCC with the same category of evidence and consensus as the reference product, bevacizumab, for this indication.	16	2	4	5
---	---	----	---	---	---